41696-97-3

Basic information

• Product Name: Benzoyl chloride, 3,5-dihydroxy- (9CI)
• Synonyms: Benzoyl chloride, 3,5-dihydroxy- (9CI);3,5-dihydroxybenzoyl chloride;BENZOYL CHLORIDE,3,5-DIHYDROXY-
• CAS NO: 41696-97-3
• Molecular Formula: C₇H₅ClO₃
• Molecular Weight: 172.5658
• Product Categories: ACIDHALIDE
• Mol File: 41696-97-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzoyl chloride, 3,5-dihydroxy- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 3,5-dihydroxy- (9CI)(41696-97-3)
• EPA Substance Registry System: Benzoyl chloride, 3,5-dihydroxy- (9CI)(41696-97-3)

Safety Data

• Hazardous Substances Data: 41696-97-3(Hazardous Substances Data)

Upstream product

• 99-10-5 3,5-Dihydroxybenzoic acid 

Downstream Products

• 934638-01-4 (3,5-bis{[2-(methyloxy)ethyl]oxy}phenyl)methanol 
• 1010413-35-0 methyl 3,5-bis{[2-(methyloxy)ethyl]oxy}benzoate 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 1461755-63-4 2,6-bis(4-methoxyphenyl)-1-methylpiperidin-4-one O-3,5-dihydroxybenzoyl oxime 
• 1453904-49-8 N-(4-(dimethylamino)phenyl)-3,5-dihydroxybenzamide 
• 1415591-15-9 C₂₇H₂₈N₂O₈ 

Relevant articles and documents

Detailed investigation of anticancer activity of sulfamoyl benz(sulfon)amides and 1H–pyrazol–4–yl benzamides: An experimental and computational study

Cancer is the second leading cause of mortality worldwide. Therapeutic approach to cancer is a multi-faceted one, whereby many cellular/enzymatic pathways have been discovered as important drug targets for the treatment of cancer. A major disadvantage of most of the currently available anticancer drugs is their non-selective cytotoxicity towards cancerous as well as healthy cells. Another major hurdle in cancer therapy is the development of resistance to anticancer drugs. This necessitates the discovery of new molecules with potent and selective cytotoxic activity towards only cancerous cells, with minimum or no damage to the normal/healthy cells. Herein we report detailed investigation into the anticancer activity of sulfamoyl benz(sulfon)amides (1a-1g, 2a-2k) and 1H–pyrazol–4–yl benzamides (3a-3j) against three cancer cell lines, breast cancer cells (MCF–7), bone-marrow cancer cells (K–562) and cervical cancer cells (HeLa). For comparison, screening against healthy baby hamster kidney cells (BHK-21) was carried out. All compounds exhibited selective cytotoxicity towards cancerous cells. Cell cycle analysis was carried out using flow cytometry, followed by fluorescence microscopic analysis. DNA interaction and docking studies were also carried out.

Synthesis, characterization and biological evaluation of N-(2,3-dimethyl-5-oxo-1-phenyl-2,5-dihydro-1H-pyrazol-4-yl)benzamides

We report the synthesis of a series of different substituted N-(2,3-dimethyl-5-oxo-1-phenyl-2,5-dihydro-1H-pyrazol-4-yl)benzamides by making use of a non-steroidal anti-inflammatory drug known as 4-aminophenazone also called as antipyrine, a compound of great interest in drug chemistry. These compounds possess potential biological applications and were screened against human recombinant alkaline phosphatase including human tissue-nonspecific alkaline phosphatase (h-TNAP), tissue specific human intestinal alkaline phosphatase (h-IAP), human placental alkaline phosphatase (h-PLAP) and human germ cell alkaline phosphatase (h-GCAP). These compounds were also tested for their inhibitory potential against recombinant human and rat ecto-5′-nucleotidases (h-e5-NT & r-e5-NT, respectively). All benzamide derivatives inhibited APs to a lesser degree than e5-NT. The reported compounds are of considerable interest for further applications in the field of medicinal chemistry as these compounds have potential to bind nucleotide protein targets.

Synthesis and Biological Activities of 1,1′-Bis(p-substituted-benzoyloxy-substituted-phenyl)cyclohexane

1,1′-Bis(p-substituted-benzoyloxy-substituted-phenyl)cyclohexane have been synthesized. Most of the compounds exhibit promising antibacterial activity and moderate anifungal activity.